Seemingly healthy 71-year-old men with minor elevations of cardiac troponin i and at risk of premature death in CVD have elevated levels of NT-proBNP: Report from the ULSAM study

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 3, 2009, Pages 418-424

  Venge, Per ^a,b   Ärnlöv, Johan ^a   Zethelius, Björn ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarker; Cardiovascular disease; Glucose metabolism; Lipid metabolism; Population based

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GLUCOSE; LIPID; TROPONIN I; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMMUNITY SAMPLE; DEATH; DISEASE ASSOCIATION; GERIATRICS; GLUCOSE METABOLISM; HEART DEATH; HEART DISEASE; HEART FUNCTION; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TARGET ORGAN; BLOOD; HEART MUSCLE; KIDNEY; LONGITUDINAL STUDY; MORTALITY; PATHOLOGY; REGRESSION ANALYSIS; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; HUMANS; KIDNEY; LONGITUDINAL STUDIES; MALE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REGRESSION ANALYSIS; RISK FACTORS; TROPONIN I;

EID: 67649684784     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510802635463     Document Type: Article

References (21)

1. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-55.
2. Venge P, Johnston N, Lagerqvist B, Wallentin L, Lindahl B. Clinical and analytical performance of the liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRISC-II substudy. Clin Chem 2003;49:880-6.
3. Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006;113:1071-8.
4. Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003;49:1331-6.
5. Hedstrand H. A study of middle-aged men with particular reference to risk factors for cardiovascular disease. Ups J Med Sci Suppl 1975;19:1-61.
6. Byberg L, McKeigue PM, Zethelius B, Lithell HO. Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances. Diabetologia 2000;43:54-60.
7. Uettwiller-Geiger D, Wu AH, Apple FS, Jevans AW, Venge P, Olson MD, Darte C, Woodrum DL, Roberts S, Chan S. Multicenter evaluation of an automated assay for troponin I. Clin Chem 2002;48:869-76.
8. Venge P, Lindahl B, Wallentin L. New generation cardiac troponin I assay for the access immunoassay system. Clin Chem 2001;47:959-61.
9. Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. Circulation 2007;116:1907-14.
10. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16.
11. Braunwald E. Changing the practice of cardiovascular medicine. Atheroscler Suppl 2001;2:27-30.
12. Poirier P, Eckel RH. Obesity and cardiovascular disease. Curr Atheroscler Rep 2002;4:448-53.
13. Topol EJ. A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2003;41(4 Suppl S):S123-9.
14. Heeschen C. Biomarkers in acute coronary syndromes and their role in diabetic patients. Diab Vasc Dis Res 2005;2:122-7.
15. James SK, Lindback J, Tilly J, Siegbahn A, Venge P, Armstrong P, Califf R, Simoons ML, Wallentin L, Lindahl B. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 2006;48:1146-54.
16. Jernberg T, James S, Lindahl B, Stridsberg M, Venge P, Wallentin L. NT-proBNP in unstable coronary artery disease - experiences from the FAST, GUSTO IV and FRISC II trials. Eur J Heart Fail 2004;6:319-25.
17. Chatha K, Alsoud M, Griffiths MJ, Elfatih A, Abozguia K, Horton RC, Dunmore SJ, Gama R. B-type natriuretic peptide in reversible myocardial ischaemia. J Clin Pathol 2006;59: 1216-17.
18. Wagner JA, Stork S, Weidemann F, Strotmann J, Fiedel C, Ertl G, Voelker W. Natriuretic peptides and myocardial oxygen supply-to-demand ratio in patients with aortic stenosis. Eur J Clin Invest 2007;37:463-71.
19. Riezebos RK, Ronner E, Tijssen JG, Laarman GJ. NT-ProBNP serum levels reflect severity and extent of ischemia in patients admitted with non-ST-elevation acute coronary syndrome. Acute Card Care 2006;8:51-7.
20. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004;18:1928-30.
21. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007;50:205-14.